Physician profile
Ali Esmaili
NPI 1760684013
$3,092.55
in general payments reported to CMS, 2019-2025
27 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $226 · 2021: $317 · 2022: $194 · 2023: $226 · 2024: $148 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.00 | 2019-2025 | |
| Janssen Biotech, INC. | $411.70 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.62 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $298.19 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $161.58 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $142.98 | 2021-2024 | Axios |
| Phathom Pharmaceuticals, INC. | $75.21 | 2025 | Voquezna |
| Genzyme Corporation | $72.95 | 2025 | |
| Novo Nordisk INC | $69.81 | 2025 | Wegovy |
| Ardelyx, INC. | $62.45 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $58.02 | 2019-2021 | |
| Madrigal Pharmaceuticals | $55.66 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $50.15 | 2025 | Dupixent |
| Biocon Biologics INC | $49.10 | 2025 | Yesintek |
| Endogastric Solutions, INC | $47.51 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $44.60 | 2020-2022 | |
| Pfizer INC. | $35.26 | 2025 | |
| Aimmune Therapeutics, INC. | $33.01 | 2025 | Zenpep |
| Smith+Nephew, INC. | $23.13 | 2020 | |
| Lilly USA, LLC | $22.92 | 2025 | Omvoh |
| Evoke Pharma, INC. | $22.83 | 2022 | |
| Vivus LLC | $18.35 | 2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $17.02 | 2021 | |
| Echosens North America, INC. | $16.20 | 2020 | |
| Allergan, INC. | $14.08 | 2019 | |
| Medtronic, INC. | $13.19 | 2022 | |
| Braintree Laboratories, INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Esmaili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.